PGI23 ESOMEPRAZOLE TREATMENT IN PATIENTS WITH UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN PRODUCTIVITYWHILE ATWORKAND IN DAILY ACTIVITIES—RESULTS FROMA RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY  by Wahlqvist, P et al.
A125Abstracts
PGI22
BURDEN OF ILLNESS IS HIGHEST IN PATIENTS WITH SEVERE
PAIN SYMPTOMS
Ten Berg MJ1, Goettsch WG1, Siiskonen SJ1,Van den Boom G2,
Smout AJPM3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht,The
Netherlands; 2Novartis Pharma B.V, Arnhem,The Netherlands;
3University Medical Centre Utrecht, Utrecht,The Netherlands
BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent
functional gastrointestinal disorder. Previous studies have shown
that the burden of illness of IBS is high. It has been suggested
that the quality of life and medical costs of IBS patients are asso-
ciated with the severity of pain. This study aimed to quantify the
burden of illness of IBS in relation to the severity of IBS symp-
toms. METHODS: Patients identiﬁed at community pharmacies
as mebeverine users were administered a questionnaire regard-
ing 1) the Rome II criteria for IBS, 2) predominant type of stool
during symptomatic episodes, 3) severity of symptoms (abdom-
inal pain and discomfort), 4) generic (SF-36) and disease-speciﬁc
quality of life (IBS-QOL), 5) current health status (utilities, 
EQ-5D and SF6D), and 6) loss of productivity. Associations
between severity of symptoms and burden of illness (including
SF-36, IBS-QOL, EQ-5D, SF6D, direct medical cost and loss 
of productivity) were assessed. RESULTS: For 168 patients, 
who met the Rome II criteria for IBS, information on severity 
of symptoms was available. The majority of patients (98, 
58%) were categorized as having severe symptoms of IBS. 47
(28%) patients were suffering from moderate symptoms and 23
(14%) patients had mild symptoms or were asymptomatic. All
components of SF-36 scored lower as the symptom severity
increased. The IBS-QOL score was lower (71.4, 95%CI:
67.5–75.3) for patients with severe symptoms than for patients
with moderate IBS and mild/asymptomatic IBS (81.8, 95%CI:
78.6–85.0 vs. 81.3, 95%CI: 75.5–87.1). The EQ-5D score was
also lower (58.3, CI95% 59.5–65.3) for patients with severe
symptoms compared to the two other groups (68.8 and 66.3).
CONCLUSIONS: This study clearly indicates that the burden of
illness of patients with IBS increases with increasing severity of
symptoms.
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OBJECTIVES: To assess the effect of acid suppression treatment
on patient-reported productivity in uninvestigated non-GERD
dyspepsia. METHODS: A clinical study aimed to investigate
whether response to a 1-week acid suppression trial with
esomeprazole is predictive of the response to four to eight weeks
of esomeprazole therapy was performed in patients with unin-
vestigated non-GERD dyspepsia (patients with predominant
symptoms of pain or burning in the center of the upper abdomen,
and who had not been previously investigated by endoscopy).
Disease-speciﬁc absence from work, reduced productivity while
at work, and reduced productivity while carrying out regular
daily activities were obtained by using the Work Productivity and
Activity Impairment (WPAI) questionnaire. Patients were ran-
domised to double-blind treatment with esomeprazole 40mgqd
or bid for 7 days, followed by either esomeprazole 40mgqd or
placebo for a further 7 weeks. Symptoms were recorded in a
daily diary. RESULTS: Before start of treatment (n = 453),
employed patients (n = 349) reported an average of 2.0 hours
absence from work and 19.8% reduced work productivity (=6.6
hours equivalent; percent reduced productivity ¥ hours actually
worked) during the past week, as well as 26.8% reduced pro-
ductivity in daily activities (all patients). In patients who were
identiﬁed as responders to the 1-week test treatment with
esomeprazole, productivity improvements were all statistically
signiﬁcant (except for hours absent from work) for esomepra-
zole versus placebo after both 4 and 8 weeks of treatment, cor-
responding to a gain of 2.0 to 3.4 work hours and 5.1 to 5.8
percent-units in daily activities per patient and week (p < 0.05).
Further analyses of the relationship between treatment response
and productivity change supported the validity of these results.
CONCLUSION: Effective acid suppression treatment with
esomeprazole in patients with uninvestigated non-GERD dys-
pepsia leads to signiﬁcant improvements in productivity while at
work and in daily activities.
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OBJECTIVES: Regular prophylactic replacement therapy has
been proved to be effective in reducing the bleeding rate and inci-
dence and/or severity of haemophilic arthropathy in children
with severe haemophilia. No study is so far available that eval-
uates efﬁcacy of prophylaxis in adolescents and adults with
haemophilia A. This study is aimed to provide cost effectiveness
evaluation of prophylaxis in adult with haemophilia A.
METHODS: A prospective, open study was designed. Patients
with haemophilia A aged 18 years or more, with frequent bleed-
ing episodes, switching from on-demand treatment to prophy-
laxis, have been enrolled. All patients were treated with a
recombinant B-domain-deleted factor VIII concentrates for all
the 6-month study period. Bleeding event rate and FVIII con-
centrate consumption (that represent 99% of total costs) have
been evaluated over on-demand treatment time period (ODT), 6
months before enrolment, and the prophylaxis time period (PT),
6 months after enrolment. Medical costs have been quantiﬁed
adopting the perspective of the third party payer, i.e. National
Health Service (NHS). RESULTS: Ten patients with a median
age of 34.0 years (23–58 years) were enrolled. Patients reported
a mean of 3.6 during ODT (median = 2.0, 1.5–15) vs. 0.51
events/patient/month during PT (median = 0.16, 0–1.7). Clotting
factor mean consumption was 22,010 during ODT (median =
17,750IU, 4500–50,000) and 28,817IU/patient/month during
PT (median = 28,333IU, 21,333–38,333). Mean cost of con-
centrates in ODT was 10,911 (median = €9607, 2193–23,500)
while during PT was 19,883 €/patient/month (median = 19,550,
14,720–26,450). The mean cost to treat one bleeding in ODT
was 3031. The incremental cost-effectiveness ratio, i.e. the cost
for bleed avoided, was €2803. CONCLUSIONS: These ﬁndings
